Original Research—Clinical| Volume 1, ISSUE 5, P785-791, 2022

Outcomes of Continuation vs Discontinuation of Adalimumab Therapy During Third Trimester of Pregnancy in Inflammatory Bowel Disease

Open AccessPublished:May 16, 2022DOI:

      Background and Aims

      Adalimumab (ADA) transport across the placenta increases with gestational age advances. We evaluated child–mother health outcomes related to the timing of the last ADA dose before delivery.


      Using IBM MarketScan data, we collected records for all children exposed to ADA during intrauterine life. We compared milestone achievements, congenital malformations, and respiratory infections rates in children from mothers of 2 groups: (1) a late ADA group, which continued therapy until 90 days or fewer before delivery; and (2) an early ADA group, which discontinued therapy more than 90 days before delivery. We also assessed the risk of flaring for mothers in the early group.


      There were no significant differences in growth (P = .48), developmental delays (P = .25), or congenital malformations (P = .61) in the 427 children of the late group vs 70 children of early ADA group. Continuing ADA late in pregnancy did not increase the respiratory infection rate (P = .38). No differences occurred between groups in cesarean and premature delivery, intrauterine growth retardation, and stillbirths. ADA discontinuation was the only predictor of flaring in the third trimester of pregnancy (odds ratio = 6.04, 95% confidence interval 2.66–13.7). In the late group, mothers’ risk of flaring decreased (16/447 vs 13/73, P < .001). Mothers with active disease were more likely to deliver prematurely vs mothers with quiet disease (6/29 vs 31/491, P = .003).


      Continuation of ADA in pregnancy close to delivery is of low risk for children. Early discontinuation, however, increases the risk of flaring in mothers and the likelihood of premature deliveries.


      Abbreviations used in this paper:

      AGA (American Gastroenterological Association), CD (Crohn’s disease), IBD (inflammatory bowel disease), ICD (International Classification of Disease), IFX (infliximab), TNF (tumor necrosis factor)
      To read this article in full you will need to make a payment
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Gastro Hep Advances
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Paramsothy S.
        • Rosenstein A.K.
        • Mehandru S.
        • et al.
        The current state of the art for biological therapies and new small molecules in inflammatory bowel disease.
        Mucosal Immunol. 2018; 11: 1558-1570
        • Kim M.A.
        • Kim Y.H.
        • Chun J.
        • et al.
        The influence of disease activity on pregnancy outcomes in women with inflammatory bowel disease: a systematic review and meta-analysis.
        J Crohns Colitis. 2021; 15: 719-732
        • Aboubakr A.
        • Riggs A.R.
        • Jimenez D.
        • et al.
        Identifying patient priorities for preconception and pregnancy counseling in IBD.
        Dig Dis Sci. 2021; 66: 1829-1835
        • Van der Woude C.J.
        • Ardizzone S.
        • Bengtson M.B.
        • et al.
        European Crohn's and Colitis Organization (ECCO), the second European evidenced-based consensus on reproduction and pregnancy in inflammatory bowel disease.
        J Crohns Colitis. 2015; 9: 107-124
        • Mahadevan U.
        • Robinson C.
        • Bernasko N.
        • et al.
        Inflammatory bowel disease in pregnancy clinical care pathway: a report from the American Gastroenterological Association IBD Parenthood Project Working Group.
        Gastroenterology. 2019; 156: 1508-1524
        • Mahadevan U.
        • Martin C.F.
        • Chambers C.
        • et al.
        Achievement of developmental milestone among offspring of women with inflammatory bowel disease: the PIANO registry [abstract].
        Gastroenterology. 2014; 146: S1
        • Truta B.
        • Leeds I.L.
        • Canner J.K.
        • et al.
        Early discontinuation of infliximab in pregnant women with inflammatory bowel disease.
        Inflamm Bowel Dis. 2020; 26: 1110-1117
        • Julsgaard M.
        • Christensen L.A.
        • Gibson P.R.
        • et al.
        Concentrations of adalimumab and infliximab in mothers and newborns, and effects on infection.
        Gastroenterology. 2016; 151: 110-119
        • Zelinkova Z.
        • van der Ent C.
        • Bruin K.F.
        • et al.
        Effects of discontinuing anti-tumor necrosis factor therapy during pregnancy on the course of inflammatory bowel disease and neonatal exposure.
        Clin Gastroenterol Hepatol. 2013; 11: 318-321
        • Julsgaard M.
        • Hvas C.L.
        • Gearry R.B.
        • et al.
        Anti-TNF therapy in pregnant women with inflammatory bowel disease: effects of therapeutic strategies on disease behavior and birth outcomes.
        Inflamm Bowel Dis. 2020; 26: 93-102
        • Hwang W.Y.
        • Foote J.
        Immunogenicity of engineered antibodies.
        Methods. 2005; 36: 3-10
        • Imai K.
        • Takaoka A.
        Comparing antibody and small-molecule therapies for cancer.
        Nat Rev Cancer. 2006; 6: 714-727
        • Seow C.H.
        • Leung Y.
        • Vande Casteele N.
        • et al.
        The effects of pregnancy on the pharmacokinetics of infliximab and adalimumab in inflammatory bowel disease.
        Aliment Pharmacol Ther. 2017; 45: 1329-1338
        • Kanis S.L.
        • De Lima-Karagiannis A.
        • Van Der Ent C.
        • et al.
        Anti-TNF levels in cord blood at birth are associated with anti-TNF type.
        J Crohns Colitis. 2018; 12: 939-947
        • Weber-Schoendorfer C.
        • Oppermann M.
        • Wacker E.
        • et al.
        Pregnancy outcome after TNF-alpha inhibitor therapy during the first trimester: a prospective multicenter cohort study.
        Br J Clin Pharmacol. 2015; 80: 727-739
        • Chambers C.D.
        • Johnson D.L.
        • Xu R.
        • et al.
        OTIS Collaborative Research Group. Birth outcomes in women who have taken adalimumab in pregnancy: a prospective cohort study.
        PLoS One. 2019; 14: e0223603
        • Moens A.
        • van der Woude C.J.
        • Julsgaard M.
        • et al.
        Pregnancy outcomes in inflammatory bowel disease patients treated with vedolizumab, anti-TNF or conventional therapy: results of the European CONCEIVE study.
        Aliment Pharmacol Ther. 2020; 51: 129-138
        • Quan H.
        • Sundararajan V.
        • Halfon P.
        • et al.
        Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data.
        Med Care. 2005; 43: 1130-1139
        • Luu M.
        • Benzenine E.
        • Doret M.
        • et al.
        Continuous anti-TNFα use throughout pregnancy: possible complications for the mother but not for the fetus. A retrospective cohort on the French national health insurance database (EVASION).
        Am J Gastroenterol. 2018; 113: 1669-1677
        • Ananthakrishnan A.N.
        • McGinley E.L.
        • Binion D.G.
        • et al.
        A novel high risk score to stratify severity of Crohn's disease hospitalizations.
        Am J Gastroenterol. 2010; 105: 1799-1807
        • Ananthakrishnan A.N.
        • McGinley E.L.
        • Binion D.G.
        • et al.
        A simple score to identify colectomy risk in ulcerative colitis hospitalizations.
        Inflamm Bowel Dis. 2009; 16: 1532-1540
        • Satsangi J.
        • Silverberg M.S.
        • Vermeire S.
        • et al.
        The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications.
        Gut. 2006; 55: 749-753
        • Quan H.
        • Li B.
        • Couris M.C.
        • et al.
        Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries.
        Am J Epidemiol. 2011; 173: 676-682
        • Abadie A.
        • Imbens G.W.
        Matching on the estimated propensity score.
        Econometrica. 2016; 84: 781-807
        • Nielsen O.H.
        • Gubatan J.M.
        • Juhl C.B.
        • et al.
        Biologics for inflammatory bowel disease and their safety in pregnancy: a systematic review and meta-analysis.
        Clin Gastroenterol Hepatol. 2022; 20: 74-87.e3
        • Mahadevan U.
        • Long M.D.
        • Kane S.V.
        • et al.
        Pregnancy and neonatal outcomes after fetal exposure to biologics and thiopurines among women with inflammatory bowel disease.
        Gastroenterology. 2021; 160: 1131-1139
        • Kanis S.L.
        • Modderman S.
        • Escher J.C.
        • et al.
        Health outcomes of 1000 children born to mothers with inflammatory bowel disease in their first 5 years of life.
        Gut. 2021; 70: 1266-1274
        • Moorthie S.
        • Blencowe H.
        • Darlison M.W.
        • et al.
        Estimating the birth prevalence and pregnancy outcomes of congenital malformations worldwide.
        J Community Genet. 2018; 9: 387-396
        • Kirby R.S.
        The prevalence of selected major birth defects in the United States.
        Semin Perinatol. 2017; 41: 338-344
        • Bornsteina E.
        • Elinerb Y.
        • Chervenaka F.A.
        • et al.
        Concerning trends in maternal risk factors in the United States: 1989-2018.
        EClinicalMedicine. 2020; 29-30: 100657
        • Martin A.J.
        • Hamilton B.E.
        • Osterman M.J.K.
        • et al.
        Births: Final Data for 2018.
        Natl Vital Stat Rep. 2019; 68: 1-47
        • Mahadevan U.
        • Martin C.
        • Dubinsky M.
        • et al.
        Exposure to anti-TNF[alpha]therapy in the third trimester of pregnancy is not associated with increased adverse out- comes: results from the PIANO registry [abstract].
        Gastroenterology. 2014; 146: S170